2025
Treatment Response to Mavacamten in Patients With Obstructive Hypertrophic Cardiomyopathy: 96-Week Results From the EXPLORER Cohort of the MAVA–Long-Term Extension Cardiac Magnetic Resonance Imaging Substudy
Saberi S, Kramer C, Oręziak A, Masri A, Barriales-Villa R, Abraham T, Lakdawala N, Wang A, Choudhury L, Rader F, Havakuk O, Stendahl J, Cardim N, Seidler T, Sherrid M, Hegde S, Kwong R, Jerosch-Herold M, Balaratnam G, Kurio G, Fox S, Olivotto I, Owens A. Treatment Response to Mavacamten in Patients With Obstructive Hypertrophic Cardiomyopathy: 96-Week Results From the EXPLORER Cohort of the MAVA–Long-Term Extension Cardiac Magnetic Resonance Imaging Substudy. Circulation 2025, 152: 905-908. PMID: 40982583, DOI: 10.1161/circulationaha.124.071188.Peer-Reviewed Original ResearchLong-Term Ambulatory Intracranial EEG.
Quraishi I, Hirsch L. Long-Term Ambulatory Intracranial EEG. Stereotactic And Functional Neurosurgery 2025, 1-20. PMID: 40892676, DOI: 10.1159/000548278.Peer-Reviewed Original ResearchIntracranial EEGLong-term intracranial recordingsCourse of epilepsyIntermittent EEGSurgical optionsClinical benefitSubclinical seizuresTreatment responseAntiseizure medicationsMonths to yearsClinically useful applicationsSeizure focusSeizure patternsCourse of monthsSeizuresPatientsMedication efficacyClinical applicationIntracranial recordingsClinical careEEGTreatmentNeurostimulationEpilepsy burdenMedicationTargeted transcriptomic analyses of tuberculosis treatment response and outcomes in The Gambia
Manneh I, Darboe F, Jobe H, Kuyateh B, Cham O, Owolabi O, Kotanmi B, Rachow A, Charalambous S, Held K, Dockrell H, Sutherland J. Targeted transcriptomic analyses of tuberculosis treatment response and outcomes in The Gambia. Frontiers In Tuberculosis 2025, 3: 1540194. DOI: 10.3389/ftubr.2025.1540194.Peer-Reviewed Original ResearchArea under the curvePoor treatment outcomesTreatment responseTreatment outcomesMonth 2Week 2Drug-susceptible tuberculosisTB treatment responseTuberculosis treatment responseEffective treatment regimensGene expressionMonitor treatment outcomesDetection of mycobacteriaTreatment regimensGood outcomeTB treatmentGene signaturePatientsTreatment monitoringPAXgene tubesRNA gene expressionDiagnosisGene expression differencesFast respondersTuberculosisPerformance of Artificial Intelligence Models in Predicting Responsiveness of Hepatocellular Carcinoma to Transarterial Chemoembolization (TACE): A Systematic Review and Meta-Analysis
Kiani I, Razeghian I, Valizadeh P, Esmaeilian Y, Jannatdoust P, Khosravi B. Performance of Artificial Intelligence Models in Predicting Responsiveness of Hepatocellular Carcinoma to Transarterial Chemoembolization (TACE): A Systematic Review and Meta-Analysis. Journal Of The American College Of Radiology 2025 PMID: 40889566, DOI: 10.1016/j.jacr.2025.08.028.Peer-Reviewed Original ResearchTransarterial chemoembolizationHepatocellular carcinoma patientsHepatocellular carcinomaPrediction model Risk Of Bias ASsessment ToolTACE treatment responsePrediction model RiskMeta-analysisCancer-related mortalityMeta-analysis aimRisk of bias assessment toolNo significant differenceTreatment responseClinical dataBias assessment toolTreatment outcomesWeb of ScienceTreatment efficacyCochrane LibraryInclusion criteriaPatientsSignificant differenceComprehensive searchChemoembolizationPerformance of artificial intelligence modelsSystematic reviewClinical Features of Chinese Patients with Thyroid Eye Disease: A Multicenter Retrospective Study
Lei C, Lyu X, Ren Y, Wei D, Zhang S, Zhang Y, Wang L, Liu L, Wen J, Liu X, Lin C, Lu W, Liu J, Li R, Zhang S, Song X, Yu Z, Bahn R, Zhou H. Clinical Features of Chinese Patients with Thyroid Eye Disease: A Multicenter Retrospective Study. Thyroid 2025 PMID: 40658134, DOI: 10.1177/10507256251359559.Peer-Reviewed Original ResearchThyroid eye diseaseSight-threatening thyroid eye diseaseTED severityRetrospective multicenter studyClinical featuresTreatment responseIntravenous glucocorticoidsMulticenter studyEye diseaseClinical features of Chinese patientsChinese cohortSevere thyroid eye diseaseFeatures of Chinese patientsClinical activity scoreMulticenter retrospective studyDegree of exophthalmosDebilitating autoimmune disorderModerate-to-severeConclusions:</i></b>Area under the receiver operating curveReceiver operating curveDiplopia scoreSight-threateningOphthalmology departmentThyroid dysfunctionWorld Health Organization risk drinking level reductions as treatment outcomes in PTSD and substance use disorder trials
López-Castro T, Gette J, Back S, Blakey S, Killeen T, Morgan-Lopez A, Norman S, Ruglass L, Saavedra L, McGovern M, Petrakis I, Sonne S, Ehring T, Brady K, Hien D. World Health Organization risk drinking level reductions as treatment outcomes in PTSD and substance use disorder trials. Drug And Alcohol Dependence 2025, 275: 112837. PMID: 40850028, DOI: 10.1016/j.drugalcdep.2025.112837.Peer-Reviewed Original ResearchConceptsPosttraumatic stress disorderSubstance use disordersAlcohol use disorderDrinking outcomesUse disorderDrinking levelsComorbid posttraumatic stress disorderWorld Health Organization risk drinking levelsWorld Health Organization’s risk levelHeavy drinkingRisk drinking levelsRisk level reductionEnd-of-treatmentSubstance use disorder trialsIntegrative data analysisStress disorderAlcohol outcomesDrinking reductionPrimary treatment endpointWorld Health OrganizationAbstinencePharmacological treatmentTreatment responseTreatment outcomesPharmacological interventionsAcceptability and feasibility of internet-based cognitive-behavioral therapy for obsessive-compulsive disorder in Brazil
de Mathis M, Flygare O, Costa D, Morais I, Rocha J, Borcato S, Shavitt R, Miguel E, Batistuzzo M, Rück C. Acceptability and feasibility of internet-based cognitive-behavioral therapy for obsessive-compulsive disorder in Brazil. Behavior Therapy 2025 DOI: 10.1016/j.beth.2025.08.001.Peer-Reviewed Original ResearchInternet-based cognitive-behavioral therapy programYale-Brown Obsessive-Compulsive ScaleInternet-based cognitive-behavioural therapyCognitive-behavioral therapy programCognitive-behavioral therapyObsessive-Compulsive ScaleObsessive-compulsive disorderOCD severityOCD treatmentResponse preventionTreatment manualsOpen-label trialDepressive symptomsTreatment respondersRE-AIM implementation science frameworkTotal scorePHQ-9OCDImplementation science frameworkPreliminary evidenceTreatment responseTherapy programRE-AIMPost-treatmentUnderserved areasIntegrating gut microbiome and neuroplasticity genomics in alcohol use disorder therapy
Koutromanos I, Legaki E, Dovrolis N, Vassilopoulos E, Stem A, Vasiliou V, Tzavellas E, Gazouli M. Integrating gut microbiome and neuroplasticity genomics in alcohol use disorder therapy. Human Genomics 2025, 19: 78. PMID: 40646629, PMCID: PMC12255058, DOI: 10.1186/s40246-025-00793-y.Peer-Reviewed Original ResearchConceptsGut microbiotaShort-chain fatty acid (SCFA)-producing bacteriaMetabolic pathwaysStress-related metabolic pathwaysHost-microbiota interactionsMicrobial metabolic pathwaysMulti-omics approachGut barrier integrityGene expression changesGene expression profilesNeuroplasticity-related genesRRNA sequencingGut microbiomeFamily genesGenomic signaturesMicrobiome compositionMicrobial compositionAUD patientsMicrobial dysbiosisTreatment responseFunctional pathwaysGene expressionMicrobiomeGenesExpression changesMicrobiome Modulation for the Treatment of Solid Neoplasms
Barragan-Carrillo R, Zengin Z, Pal S. Microbiome Modulation for the Treatment of Solid Neoplasms. Journal Of Clinical Oncology 2025, 43: 2734-2738. PMID: 40644647, PMCID: PMC12352565, DOI: 10.1200/jco-25-00374.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerImmune checkpoint inhibitorsRenal cell carcinomaResponse to immune checkpoint inhibitorsImmune checkpoint inhibitor benefitImmune checkpoint inhibitor initiationTreatment of solid neoplasmsICI-based regimensCell lung cancerDietary fiber intakeAssociated with higher ratesFecal microbiota transplantationMicrobiome modulationCheckpoint inhibitorsGut microbiomeCell carcinomaSolid neoplasmsPrimary resistanceShorter survivalClinical outcomesPreclinical studiesTreatment responseFiber intakeLung cancerClinical activityCognitive‐Behavioral Therapy and Lisdexamfetamine, Alone and Combined, for Binge‐Eating Disorder: Secondary Outcomes of a Randomized Controlled Trial
Grilo C, Ivezaj V, Yurkow S, Tek C, Gueorguieva R. Cognitive‐Behavioral Therapy and Lisdexamfetamine, Alone and Combined, for Binge‐Eating Disorder: Secondary Outcomes of a Randomized Controlled Trial. International Journal Of Eating Disorders 2025 PMID: 40631364, PMCID: PMC12268943, DOI: 10.1002/eat.24502.Peer-Reviewed Original ResearchCognitive-behavioral therapyOvervaluation of shape/weightDifferential treatment responseRandomized Controlled TrialsBinge-eating disorderCognitive-behavioralDelay discountingBinge eatingPosttreatment assessmentLisdexamfetamineTreatment responseSecondary outcomesControlled TrialsTreatment effectsIndividualized treatmentBinge-eatingShape/weightBingePrimary outcomeEatingSignificant improvementDisordersMetabolic variablesPosttreatmentSignificant effectLinguistic predictors of response to internet-based written CBT for PTSD symptoms of 9/11 world trade center recovery workers and survivors
Leska T, Schreiber Z, Astorino E, Verghese M, Markowitz J, Seeley S, Brinkman H, Kowalchyk M, Cahn L, Aaronson C, Boettche M, Knaevelsrud C, Pietrzak R, Feder A. Linguistic predictors of response to internet-based written CBT for PTSD symptoms of 9/11 world trade center recovery workers and survivors. Journal Of Affective Disorders 2025, 391: 119828. PMID: 40623644, DOI: 10.1016/j.jad.2025.119828.Peer-Reviewed Original ResearchConceptsPosttraumatic stress disorderCognitive-behavioral therapyPosttraumatic stress disorder symptomsAssociated with greater improvementPCL-5Linguistic predictorsTrauma-focused cognitive-behavioral therapyPosttraumatic Stress Disorder ChecklistPTSD symptom improvementGreater improvementTreatment responseWorld Trade Center rescueDSM-5Behavioral wordsStress disorderWord categoriesMotion wordsTestimonial therapyPredictors of responseRecovery workersSymptom improvementLinguistic InquiryPost-treatmentWritten narrativesDisordersSerum kynurenine metabolites and cytokine levels: diagnostic and predictive implications in acute manic episodes of bipolar disorder
Li W, Liu Z, Wang J, Wang X, Chen W, Li N, Huang J, Gou M, Zhang P, Liu R, Deng H, Yang K, Chen S, Xie T, Tian L, Yang F, Tian B, Li C, Li Y, Tan Y. Serum kynurenine metabolites and cytokine levels: diagnostic and predictive implications in acute manic episodes of bipolar disorder. Brain Behavior And Immunity 2025, 129: 485-493. PMID: 40578536, DOI: 10.1016/j.bbi.2025.06.033.Peer-Reviewed Original ResearchYoung Mania Rating ScaleKynurenine metabolitesHealthy controlsTreatment outcomesCytokine levelsKynurenine metabolite levelsManic episodes of bipolar disorderBipolar disorderAcute manic episodeMania Rating ScaleEpisodes of bipolar disorderWeeks of treatmentInterleukin (IL)-10Predicting Treatment OutcomePredictors of treatment outcomeManic symptom severitySerum cytokinesSerum levelsTreatment responseIL-4Diagnostic accuracyIL-10Cytokine systemManic episodesIL-8Phenotyping extracellular vesicles and their serotonin transporter cargo in major depressive disorder
Zadka Ł, Eggerstorfer B, Buzalewicz I, Vraka C, Rusak A, Godbersen G, Opalińska A, Unterholzner J, Ulatowska-Jarża A, Philippe C, Haczkiewicz-Leśniak K, Silberbauer L, Murgaš M, Nics L, Hahn A, Hacker M, Gomułkiewicz A, Rujescu D, Podhorska-Okołów M, Lanzenberger R, Gryglewski G. Phenotyping extracellular vesicles and their serotonin transporter cargo in major depressive disorder. Journal Of Affective Disorders 2025, 389: 119740. PMID: 40550277, DOI: 10.1016/j.jad.2025.119740.Peer-Reviewed Original ResearchSerotonin transporterDepressive disorderPresence of serotonin transporterAntidepressant treatment responseSerotonin transporter levelsMDD patientsNanoparticle tracking analysisMood disordersPsychiatric disordersMDDBinding potentialExtracellular vesiclesTreatment response predictionPositron emission tomographyTreatment responseDisordersHealthy controlsExosome markers CD63Blood-brain barrierEmission tomographyStudy intercellular communicationPrognostic valueConcentration of extracellular vesiclesPatient stratificationExosomal markers719-P: Oral Disposition Index (oDI) as an Outcome Measure in Type 1 Diabetes (T1D) Clinical Trials—Evidence from Stage 1 and Stage 2 Trials
GALDERISI A, CUTHBERTSON D, PETRELLI A, MORAN A, SOSENKO J, JACOBSEN L, LIBMAN I, REDONDO M, ISMAIL H. 719-P: Oral Disposition Index (oDI) as an Outcome Measure in Type 1 Diabetes (T1D) Clinical Trials—Evidence from Stage 1 and Stage 2 Trials. Diabetes 2025, 74 DOI: 10.2337/db25-719-p.Peer-Reviewed Original ResearchOral disposition indexC-peptide indexAUC C-peptideC-peptideMarkers of treatment effectivenessStage 1B cell functionYear of treatmentC-peptide measurementsType 1 diabetesPlacebo armMeasure of B-cell functionStage 2T1D prevention trialsTreatment responseTreated armClinical trialsDisposition indexSensitive markerPrevention trialsMetabolic endpointsLong-term effectsInsulin secretionOutcome measuresTeplizumabPain Reduction Following Eptacog Beta Treatment of Bleeding Episodes in Adolescents and Adults With Haemophilia A or B Complicated by Inhibitors
Buckner T, Kessler C, Castaman G, Hermans C, Jiménez‐Yuste V, Mahlangu J, Miesbach W, Oldenburg J, Recht M, Valentino L, Wheeler A, Pipe S. Pain Reduction Following Eptacog Beta Treatment of Bleeding Episodes in Adolescents and Adults With Haemophilia A or B Complicated by Inhibitors. Haemophilia 2025, 31: 713-721. PMID: 40534395, DOI: 10.1111/hae.70077.Peer-Reviewed Original ResearchInitial dosing regimensVisual analogue scaleBleeding episodesScore reductionReceiver Operating CharacteristicEptacog betaPain reductionPain levelsTreatment responseVisual analogue scale score reductionBeta treatmentTreatment outcomesMean VAS scorePain score reductionTreat bleeding episodesVAS score reductionBaseline pain levelsAssess treatment responseEvaluate treatment responseEvaluate pain reductionControl of bleedingPredicting Treatment OutcomePost hoc studyPatient-reported outcomesBleed resolutionGenetics of Response to ECT, TMS, Ketamine and Esketamine
Franklin C, Altinay M, Bailey K, Bhati M, Carr B, Conroy S, Khurshid K, McDonald W, Mickey B, Murrough J, Nestor S, Nickl‐Jockschat T, Reti I, Sanacora G, Trapp N, Viswanath B, Wright J, Zandi P, Potash J. Genetics of Response to ECT, TMS, Ketamine and Esketamine. American Journal Of Medical Genetics Part B Neuropsychiatric Genetics 2025, 198: 88-102. PMID: 40525674, PMCID: PMC12230785, DOI: 10.1002/ajmg.b.33038.Peer-Reviewed Original ResearchGenome-wide association studiesSingle nucleotide polymorphismsTreatment responseEffects of variantsElectroconvulsive therapyGenetic predictors of treatment responseTreatment modalitiesAssociation studiesCandidate genesFactors affecting treatment responseAssociated with treatment responseResponse to available treatmentsGene studiesNucleotide polymorphismsTreatment-resistant mood disordersGenetic predictors of responseTreatment-resistant depressionPredictors of treatment responsePredictors of responseGroup of patientsGenesTranscranial magnetic stimulationGeneticsGenetic predictorsClinical responseThe role of long non-coding ribonucleic acid HOXA11-AS in endometriosis therapy
Mamillapalli R, Gawde N, Fay M, Atwani R, Moridi I, Taylor H. The role of long non-coding ribonucleic acid HOXA11-AS in endometriosis therapy. Reproductive Biology And Endocrinology 2025, 23: 83. PMID: 40457415, PMCID: PMC12128536, DOI: 10.1186/s12958-025-01420-0.Peer-Reviewed Original ResearchConceptsHOXA11-ASHOXA11-AS expressionEutopic endometriumLong non-coding RNAsEctopic endometriotic lesionsEndometriotic cell linesInvasion of endometriosisEndometrial stromal cellsReal-time polymerase chain reactionNon-coding RNAsEndometriotic lesionsEndometriosis therapyEndometriosis patientsNormal endometriumProgestin responsivenessEndometrial developmentTreatment responsePolymerase chain reactionQuantitative real-time polymerase chain reactionEndometriosisEndometriosis treatmentMethodsTissue samplesStromal cellsPotential target genesEndometriumThe prevalence, clinical impact, and therapeutic considerations of trauma in adults with bipolar disorder: A systematic review
Xiao K, Sayed H, Xing J, Zhang X, Ai J, Teopiz K, Ho R, Rhee T, Lo H, Guillen-Burgos H, Vinberg M, McIntyre R. The prevalence, clinical impact, and therapeutic considerations of trauma in adults with bipolar disorder: A systematic review. Journal Of Affective Disorders 2025, 388: 119507. PMID: 40449746, DOI: 10.1016/j.jad.2025.119507.Peer-Reviewed Original ResearchBipolar disorderSevere stressful life eventsChildhood emotional maltreatmentChildhood physical maltreatmentStressful life eventsEffects of traumaImpact of traumaChildhood traumaClinical impactEmotional maltreatmentSymptom severityLife eventsPhysical maltreatmentTherapeutic considerationsIllness severityIntegrated model of careModerating effectTreatment responseTreatment outcomesSystematic reviewAssociated with poor prognosisMaltreatmentModality of treatmentNegative clinical impactHistory of traumaBiosocial Variation in Treatment Response to GLP-1s: Implications for Clinical Care and Health Policy
Horwitz R, Otaka S, Conroy A, Cullen M, Matory A, Singer B, Sim I. Biosocial Variation in Treatment Response to GLP-1s: Implications for Clinical Care and Health Policy. The American Journal Of Medicine 2025, 138: 1346-1351. PMID: 40393609, DOI: 10.1016/j.amjmed.2025.05.016.Peer-Reviewed Original ResearchTreatment-resistant obesityTrajectory of obesityResponse to treatmentObesity-related disordersRandomized Controlled TrialsReal-world evidence studiesTreatment responseClinical managementEvidence studiesGLP-1sControlled TrialsPatientsObesityWeight lossBody weightPathogenesisAverage treatment responseHealth policyTreatmentPhysiological systemsMulti-ancestry genome-wide association meta-analysis of buprenorphine treatment response
Davis C, Khan Y, Crist R, Vickers-Smith R, Hartwell E, Gelernter J, Kampman K, Kember R, Le Moigne A, Laffont C, Kranzler H. Multi-ancestry genome-wide association meta-analysis of buprenorphine treatment response. Neuropsychopharmacology 2025, 50: 1346-1353. PMID: 40328918, PMCID: PMC12260092, DOI: 10.1038/s41386-025-02117-z.Peer-Reviewed Original ResearchGenome-wide association studiesTreatment responseOpioid use disorderGenome-wide significant lociGWAS meta-analysesCross-ancestry meta-analysisClinical characteristicsGenome-wide association meta-analysisGenetic predictors of treatment responseMeta-analysisPresence of chronic painAssociation meta-analysisUse disorderPartial agonist buprenorphinePhenome-wide association analysisTreat opioid use disorderPredictors of treatment responseExtended-release buprenorphineMillion Veteran ProgramSignificant lociLead variantsCross-ancestryAssociation studiesOdds of treatment responseAssociation analysis
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply